Second quarter 2024 results
Second quarter 2024 results were reviewed by management during a conference call with the financial community. The presentation was followed by a Q&A session.
Thursday July 25, 2024
14:30 - 16:00 CET (8:30am – 10am EST)
Featuring
Paul Hudson
Chief Executive Officer
François Roger
Chief Financial Officer
Houman Ashrafian
Head of Research and Development
Highlights
We are continuing our strong performance in 2024, with broad-based, double-digit sales growth in the second quarter, and making important progress in our pipeline of new medicines.
Paul Hudson
Chief Executive Officer